Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

rudazur2 Aug. 25 at 9:08 PM

$CAPR at this rythm we will get deliste in weeks

1 · Reply

AlexTrades2 Aug. 25 at 9:02 PM

$CAPR added a few more at support. biotechs got beat up today

0 · Reply

Rascal7777 Aug. 25 at 9:00 PM

$CAPR I just never thought we woukd see these levels again.

0 · Reply

Rascal7777 Aug. 25 at 8:57 PM

$CAPR this is so stressful.

0 · Reply

MrsBelfort Aug. 25 at 8:49 PM

$CAPR We are in a market where StealthX is being completely ignored. I think Prasad completely broke the stock price here with their advised CRL. We are being unfairly judged by execution especially by algos that might not know any better.

0 · Reply

crazyt Aug. 25 at 8:46 PM

$CAPR Linda should borrow OTLK's playbook. They got crl's and went ahead and applied for EMA. They got approved and will sell their drug in Europe. In the meantime, they turn around and reapplied for FDA approval. Their PDUFA date is 8/27. Am watching to see if they get approved. Linda has to move forward.

1 · Reply

profitraider Aug. 25 at 8:46 PM

$CAPR Listen you, I told you this was going to happen but you didn’t want to listen!

0 · Reply

ripztrip Aug. 25 at 8:44 PM

$CAPR Following the Type A meeting and potentially positive HOPE-3 data, Capricor will resubmit the BLA in Q3 2025, expecting a new review cycle to begin. Goal: The goal is to get deramiocel through the approval process and provide a much-needed treatment for the DMD community.

0 · Reply

Phillvsthemarket Aug. 25 at 8:34 PM

$CAPR 1: When do you expect the results of HOPE 2 data to be released? 2: Any news in regards to CMC/ manufacturing concerns ? Was this addressed yet or we don’t know that yet I will jump all in soon once I am done with BTAI this week. I would appreciate your serious inputs .

1 · Reply

creditgoo Aug. 25 at 8:34 PM

$CAPR added 🤡 🤪

0 · Reply

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 7 days ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 17 days ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 19 days ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 25 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 26 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 26 days ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 25, 2025, 11:21 AM EDT - 4 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Jul 17, 2025, 4:46 PM EDT - 5 weeks ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 5 weeks ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 6 weeks ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 6 weeks ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Jul 11, 2025, 4:53 PM EDT - 6 weeks ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 9:03 AM EDT - 6 weeks ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 8:20 AM EDT - 6 weeks ago

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

FEIM

Jul 11, 2025, 6:36 AM EDT - 6 weeks ago

US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:30 AM EDT - 6 weeks ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jun 24, 2025, 2:51 PM EDT - 2 months ago

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

Jun 24, 2025, 9:16 AM EDT - 2 months ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 23, 2025, 12:46 PM EDT - 2 months ago

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Jun 20, 2025, 3:11 PM EDT - 2 months ago

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Jun 20, 2025, 9:25 AM EDT - 2 months ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Jun 17, 2025, 9:00 AM EDT - 2 months ago

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Jun 11, 2025, 5:18 PM EDT - 2 months ago

Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement

Jun 11, 2025, 9:25 AM EDT - 2 months ago

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

Jun 3, 2025, 10:00 AM EDT - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation

Jun 1, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect

May 30, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out

May 29, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation

May 28, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 3 months ago

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect

May 23, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation

rudazur2 Aug. 25 at 9:08 PM

$CAPR at this rythm we will get deliste in weeks

1 · Reply

AlexTrades2 Aug. 25 at 9:02 PM

$CAPR added a few more at support. biotechs got beat up today

0 · Reply

Rascal7777 Aug. 25 at 9:00 PM

$CAPR I just never thought we woukd see these levels again.

0 · Reply

Rascal7777 Aug. 25 at 8:57 PM

$CAPR this is so stressful.

0 · Reply

MrsBelfort Aug. 25 at 8:49 PM

0 · Reply

crazyt Aug. 25 at 8:46 PM

1 · Reply

profitraider Aug. 25 at 8:46 PM

$CAPR Listen you, I told you this was going to happen but you didn’t want to listen!

0 · Reply

ripztrip Aug. 25 at 8:44 PM

0 · Reply

Phillvsthemarket Aug. 25 at 8:34 PM

1 · Reply

creditgoo Aug. 25 at 8:34 PM

$CAPR added 🤡 🤪

0 · Reply

ripztrip Aug. 25 at 8:29 PM

$CAPR

0 · Reply

scaredmoneymakenomoney Aug. 25 at 8:26 PM

$CAPR added.

0 · Reply

INTELLECTUAL_NINJA Aug. 25 at 8:23 PM

$CAPR

0 · Reply

INTELLECTUAL_NINJA Aug. 25 at 8:17 PM

$CAPR

0 · Reply

MARK1AMY Aug. 25 at 8:15 PM

$CAPR This is way too painful to watch the daily. I think I’ll just ignore and look at it 3 years from now, because at this pace that’s how long before an approval decision. F’n ridiculous!

1 · Reply

kevdapaul Aug. 25 at 8:09 PM

$CAPR so srpt brought this down or combo of a market drop?

0 · Reply

prfcnthtmi05 Aug. 25 at 8:04 PM

$CAPR - how many times we are going to play this game ? why did I not ? we may listen this soon

0 · Reply

jimmy18000 Aug. 25 at 8:04 PM

$CAPR not surprised with XBI down 2.5%..were a day closer to the minutes and to data release.

0 · Reply

Buymycheapies Aug. 25 at 8:00 PM

$CAPR need the bell to put us out of our misery for today

0 · Reply

topstockalerts Aug. 25 at 7:52 PM

$CAPR keep an eye for AH..

1 · Reply

TooHot_toTouch Aug. 25 at 7:51 PM

$CAPR I might be in the minority here but bringing in a large bio partner who can muscle this through might not be a bad idea. Sure the terms would be way more favorable at $20+/share vs $6.50/share but a portion of the pie vs no pie might be what we are looking at.

3 · Reply

rhealarson Aug. 25 at 7:50 PM

$CAPR UTRX squeeze math looking silly 😎 float tight buyers aggressive catalysts stacking targets 0.50 then 0.75 if momentum funds pile

0 · Reply

Market Cap	324.59M
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-181.72%
Debt to Equity Ratio	0.00

Volume	1,954,970
Avg Vol	2,682,806
Day's Range	N/A - N/A
Shares Out	45.72M
Stochastic %K	12%
Beta	0.59
Analysts	Strong Sell
Price Target	$20.60